April 27, 2023 by admin aurigene Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
April 27, 2023 by admin aurigene Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
April 27, 2023 by admin aurigene An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity
April 27, 2023 by admin aurigene Oral Immune Checkpoint Antagonists Dually Targeting TIGIT and PD-1 pathways for Cancer Therapy
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers